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A B S T R A C T
The purpose of the present research was to develop a suitable, simple, precise, accurate,
robust, and reproducible RP-HPLC method for a reliable simultaneous quantification of
docetaxel (DTX) and curcumin (CCM) in rat plasma samples using paclitaxel (PTX) as an
internal standard. The samples were assayed by the Agilent 1260 Infinity HPLC instrument
using a Capcell Pak C8 column (4.6 mm × 150 mm, 5 μm) under isocratic conditions.Themobile
phase consisted of acetonitrile and triple distilled water (40/60, v/v) with a flow rate of
1.0 ml/min. The eluent was monitored at 230 nm for simultaneous measurement of curcumin
and docetaxel.The method was validated by determining system suitability, selectivity, sen-
sitivity, linearity, inter-day and intra-day precision, accuracy, robustness, and stability in
accordance with the guidelines of the United States Food and Drug Administration (FDA).
The developed chromatographic method proved to be simple, precise, accurate, robust and
reproducible. Moreover, the samples showed stability at room temperature over a period
of 48 h. Thus, this method would be employed for routine simultaneous quantification of
docetaxel and curcumin in rat plasma samples.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Docetaxel [4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1,7β,10β-
trihydroxy-9-oxotax-11-ene-11α-yl-(2R,3S)-3-tert-butoxy-
carbonylamino-2-hydroxy-3-phenylpropionate] (Fig. 1A) is a
semisynthetic chemotherapeutic agent derived from a natural
inactive precursor 10-deacetyl baccatin III, extracted from leaves
of Taxus baccata [1,2]. Docetaxel is approved by the United States
Food and Drug Administration (FDA) for the treatment of cas-
tration resistant prostate cancer (CRPC) [3]. It possesses
promising antineoplastic effects against a variety of other
tumors as well [4–10]. Docetaxel possesses very poor oral
bioavailability [11] due to its practical insolubility in water
(4.93 μg/ml) [12] and great affinity to the multidrug efflux pump
P-glycoprotein (P-gp) [13]. In long-term therapy, resistance is
developed against docetaxel due to excessive activation of PI3K/
AKT signaling in CRPC cells [14,15].Accordingly, down-regulation
of PI3K/AKT signaling in CRPC cells augments the effective-
ness of docetaxel [16]. Curcumin is a hydrophobic polyphenolic
compound (Fig. 1B) extracted from the rhizomes of Curcuma
longa. It is a potent chemoprotective and chemotherapeutic
active substance against a broad spectrum of neoplasias [17–20].
Also, it has been reported to have some anti-inflammatory prop-
erties. Curcumin inhibits the PI3K/AKT pathway [21,22].
Therefore, curcumin exerts useful synergistic effects when used
concomitantly with docetaxel [23,24].
A number of HPLC methods have been described for quan-
tification of docetaxel in plasma samples, alone [25–29] or in
combination with other drugs [30]. Moreover, several methods
have been described for simultaneous determination of
curcumin and other drugs in various pharmaceutical prepa-
rations [31–33]. However, simultaneous determination of
docetaxel and curcumin in rat plasma samples has not been
reported previously.Thus, the present investigation was aimed
to develop a suitable, simple, precise, accurate, robust, and re-
producible RP-HPLC method for simultaneous estimation of
docetaxel and curcumin in rat plasma. Paclitaxel was used as
an internal standard. The validation of the method was ac-
complished according to Food and Drug Administration (FDA)
guidelines [34].
2. Materials and methods
2.1. Materials
Analytical standard grade curcumin (assay ≥ 98%; Sigma-
Aldrich; St. Louis, MO, USA), paclitaxel (assay ≥ 98%; Sigma-
Aldrich, St. Louis, MO, USA) and docetaxel (assay ≥ 98%; Bertin
Pharma; Montigny le Bretonneux, France) pure forms were
kindly provided by Hanmi Pharm. Co. (Hwasung, South Korea).
The HPLC grade acetonitrile was purchased from Avantor Per-
formance Materials, Inc. (Center Valley, PA, USA). Deionized
water was obtained using Milli-Q system (Millipore; Molsheim,
France). All other reagents and solvents used in this study were
of analytical grade.
2.2. Instrument and chromatographic conditions
Chromatographic analysis was performed using theAgilent 1260
Infinity HPLC system (Agilent Technologies, Santa Clara, CA,
USA) equipped with ChemStation software, G1311C 1260 Quat
Pump, G1314B 1260VWDVL detector and Capcell Pak C8 column
(Shiseido; Tokyo, Japan, 4.6 mm I.D. × 150 mm, 5 μm). The
column temperature was set at 40 °C. The mobile phase con-
sisted of acetonitrile and triple distilled water (40/60, v/v) was
used for isocratic elution at a flow rate of 1.0 ml/min. The in-
jection volume was 10 μl. The eluent was monitored at 230 nm
for simultaneous detection of curcumin and docetaxel over a
period of 20 min.
2.3. Preparation of standard solutions
Accurately weighed DTX and CCM (100 mg each) were poured
into a 100 ml measuring flask. They were dissolved together
in 100 ml of acetonitrile to get the stock solution with a final
concentration of 1 mg/ml for each analyte. Similarly, 10 mg PTX
(internal standard) was dissolved in 100 ml acetonitrile in a
measuring flask to get a 100 μg/ml concentration. Six stan-
dards with 3.125, 6.25, 12.5, 25, 50 and 100 μg/ml concentrations,
to be used in the preparation of samples for calibration curves
of DTX and CCM, were derived from the stock solution of DTX
and CCM. The standards with 6.25, 10, 50, 75 and 100 μg/ml
strengths, to be used in the preparation of samples for testing
the other validation parameters, were also derived from the
above-mentioned stock solution of DTX and CCM.
2.4. Sample preparation
Male Sprague-Dawley rats, weighing 250–280 g, were acquired
from Orient Bio (Seongnam, South Korea).The procedure for the
animal study was consistent with NIH Policy and the Animal
Welfare Act under the approval of the Institutional Animal CareFig. 1 – Chemical structure: (A) docetaxel; (B) curcumin.
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and Use Committee (IACUC) at Hanyang University.All the blank
rat plasma samples were prepared by a protein precipitation
technique. Each standard strength (50 μl) and internal stan-
dard (50 μl) was added to 100 μl of blank rat plasma in a
microtube and vortex-mixed.Then, 1ml of acetonitrile was added
to precipitate the plasma proteins. After vortex-mixing (2 min)
and centrifugation (10min at 3000 g), the supernatant was trans-
ferred to a clean microtube and evaporated using a vacuum
centrifugal evaporator.The residue was reconstituted with 100 μl
of acetonitrile, vortexed for 1min and centrifuged again for 5min
at 11,000 g. Then, 10 μl of the resulting solution was analysed
by the HPLC method as described above.
2.5. Validation of the HPLC method
2.5.1. System suitability
The system suitability was assured by determining peak re-
tention time, peak area, theoretical plates and tailing or
asymmetry factor for DTX, CCM and PTX.The ideal values for
system suitability are CV < 1%, asymmetry factor < 2 and theo-
retical plates >2000 [35]. The standard concentration of
6.25 μg/ml was used in the preparation of the samples. The
sample preparation was accomplished in accordance with the
method as described above in Section 2.4; therefore, the final
nominal concentration, to be detected by the describedmethod,
was 3.125 μg/ml. Six replicate samples were assayed for de-
termining the system suitability.
2.5.2. Selectivity
The blank samples of rat plasma, prepared according to the
method as described in Section 2.4 but without analytes, were
analysed in order to test the matrix effect. Selectivity was also
ensured at the LLOQ. The plasma was obtained from six rats.
Moreover, the plasma samples, obtained from the right femoral
artery of the rats after concomitant administration of a dose
of DTX and CCM via the oral route (in vivo testing), were also
extracted according to the method described in Section 2.4, and
analysed by the HPLC method as described above. Then, the
samples were tested for possible interference of metabolites.
2.5.3. Sensitivity
The sensitivity for simultaneous determination of DTX and CCM
was evaluated with respect to CCM peak. The limit of detec-
tion (LOD) and lower limit of quantification (LLOQ) were
determined by calculating the signal/noise ratio (S/N). The
sample preparation was accomplished in accordance with the
method as described above in Section 2.4. According to the FDA
guidelines, the analyte response (signal) at the LLOQ should
be at least 5-times the response compared to blank response
(noise). Moreover, the actual concentrations measured should
have a precision of <20% of CV and accuracy within 20% of the
nominal concentration [34].
2.5.4. Linearity
Six standard concentrations of 3.125, 6.25, 12.5, 25, 50 and
100 μg/ml were used in the preparation of calibration samples
of DTX. Similarly, six standard strengths with 3.125, 6.25, 12.5,
25, 50 and 100 μg/ml were employed for the preparation of
calibration samples of CCM.All the samples were prepared ac-
cording to the method as described above in Section 2.4.
Therefore, the nominal concentrations of DTX, to be analysed
by HPLC, were 1.5625, 3.125, 6.25, 12.5, 25 and 50 μg/ml, re-
spectively. Likewise, the nominal concentrations of CCM after
sample preparation were 1.5625, 3.125, 6.25, 12.5, 25 and
50 μg/ml, respectively. The slope, intercept and correlation co-
efficient (r2) were calculated for regression analysis of DTX and
CCM. According to the FDA guidelines, the calibrators should
not deviate by more than 15% of the nominal concentrations,
except at LLOQ where the calibrator should not deviate by more
than 20% [34].
2.5.5. Accuracy
The accuracy was determined by the percent recovery method.
Three standard concentrations of 10 μg/ml, 75 μg/ml and
100 μg/ml were used in the preparation of samples.The samples
were prepared according to the method as described above in
Section 2.4; thus, the final nominal concentrations, to be assayed
by the describedmethod,were 5 μg/ml, 37.5 μg/ml and 50 μg/ml,
respectively. For each sample, the actual concentration was de-
termined and the mean percent recovery was calculated (n = 6).
According to the FDA guidelines, the mean value should be
within 15% of the nominal value, except at LLOQ where it
should not deviate by more than 20% [34].
2.5.6. Precision
For evaluating precision, intra-day and inter-day variances were
determined over 1 day and 3 days, respectively. Three stan-
dard concentrations of 10, 75 and 100 μg/ml were used in the
preparation of samples. All the samples were prepared in ac-
cordance with the method as described above in Section 2.4;
thus, the final nominal concentrations to be assayed were 5,
37.5 and 50 μg/ml, respectively.The %CVwas calculated for each
sample analysed. According to the FDA guidelines, the preci-
sion determined at each concentration should not exceed 15%
of the CV, except for the LLOQ where it should not exceed 20%
of the CV [34].
2.5.7. Robustness
The effect of slight deliberate variation in chromatographic pa-
rameters such as column temperature, mobile phase flow rate
andmobile phase composition on retention time and peak area
ratio was observed one by one. The standard strength used in
the preparation of the sample for this test was 100 μg/ml. The
sample preparation was done according to the method as de-
scribed above in Section 2.4; therefore, the final nominal
concentration to be assayed was 50 μg/ml. The mean reten-
tion time and mean peak area ratio were determined for DTX
and CCM against each setting (n = 6).
2.6. Stability
The standard with 50 μg/ml concentration was used in the
preparation of samples for testing the stability. The samples
were prepared in accordance with the method as described
above in Section 2.4; therefore, the final nominal concentra-
tion was 25 μg/ml.The stability of CCM and DTX in the prepared
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sample was determined by analysing concentration at 1, 6, 12,
24 and 48 h. The concentration was determined for CCM and
DTX at each time point (n = 3).
3. Results and discussion
Docetaxel and curcumin are hydrophobic compounds which
are practically insoluble in water [12,36]. On the other hand,
they are freely soluble in acetonitrile. In the present HPLC
method, acetonitrile and triple distilled water (40/60, v/v) were
used as mobile phases A and B, respectively. In a preliminary
separate analysis study of CCM and DTX, not C18 but C8 column
was successfully used; therefore, C8 column was easily avail-
able for their simultaneous determination. The described
chromatographic conditions resulted in CCM, DTX and PTX re-
tention at about 10.47 ± 0.29, 14.26 ± 0.21 and 16.19 ± 0.12
minutes, respectively (Fig. 2).
According to the USP, the HPLC method is considered suit-
able when the CV of peak area < 1%, the tailing factor < 2 and
the theoretical plates > 2000 [35]. The results of system suit-
ability are shown in Table 1. All the measured parameters are
within the recommended limits. Thus, our results suggested
that the described method was suitable for the simultaneous
determination of DTX and CCM using PTX as an internal
standard.
During testing selectivity, the analyses of blank samples gen-
erated some peaks within about 4 minutes of detection time.
After 4 minutes, prominent signals did not appear in the chro-
matograms (data not shown). Moreover, the analyses of the
analyte-containing samples exhibited well-differentiated peaks
of the analytes at their respective retention times, even at the
lower concentrations (Figs. 2, 3). Furthermore, the analyses of
the plasma samples, withdrawn from rats (via the right femoral
artery) after administering a dose of DTX and CCM via the oral
route (in vivo testing), showed chromatograms similar to those
of the samples tested in vitro. No additional peak, interfering
with the analyte-peaks, was seen in the chromatogram (Fig. 4).
Accordingly, our results suggested that the described analyti-
cal method demonstrated selectivity in both in vitro and in vivo
samples.
At the same concentration, the described method re-
sulted in a relatively shorter peak corresponding to CCM than
that corresponding to DTX; therefore, LOD and LLOQ for si-
multaneous determination of CCM and DTXwere recorded with
respect to CCM peak in our study. Fig. 3A and B shows the chro-
matograms corresponding to 1.5625 μg/ml and 3.125 μg/ml
which resulted in an S/N ratio (mean ± SD, n = 6) of 3.03 ± 0.50
and 10.40 ± 0.87 for CCM, respectively. Accordingly, they were
nominated as LOD and LLOQ, respectively. At LLOQ, the value
of S/N ratio >5, a precision of the actual concentration of <20%
of CV and an accuracy within 80–120% showed that they were
within the recommended limits mentioned in the FDA guide-
lines [34].
The range for constructing the calibration curves of DTX
and CCM was 1.5625–50 μg/ml (Fig. 5A, B). The response was
linear throughout the range for both analytes (r2 = 0.9999 and
r2 = 0.9997, respectively). The regression analysis is shown in
Table 1 – System suitability.
Parameter Curcumin Docetaxel Paclitaxel
Peak area 53.44 ± 0.19 73.11 ± 0.24 1025.69 ± 0.23
Retention time 10.47 ± 0.29 14.26 ± 0.21 16.19 ± 0.12
Theoretical plates 3553.33 ± 0.24 5559.50 ± 0.27 5759.67 ± 0.30
Tailing factor 0.67 ± 0.59 1.14 ± 0.35 1.15 ± 0.26
Each value denotes the mean ± %CV (n = 6).
Fig. 2 – Chromatogram showing retention time of peaks of interest.
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Table 2. According to the FDA guidelines, the calibrators should
not deviate by more than 15% of the nominal concentrations,
except at LLOQ,where the calibrator should not deviate bymore
than 20% [34]. All the concentrations determined were within
85–115% of the corresponding nominal concentrations; there-
fore, the method exhibited linearity.
The accuracy was assessed by the percent recovery method.
The accuracy data are shown in Table 3. According to the FDA
guidelines, themean value should be within 15% of the nominal
value, except at LLOQ,where it should not deviate by more than
20% [34]. All the accuracy values were within 85–115% of the
recovery range. Thus, our results suggested that the de-
scribed method was accurate.
The precision was determined by %CV. The inter-day and
intra-day precision data are shown in Table 4. According to the
FDA guidelines, the precision determined at each concentra-
tion should not exceed 15% of the CV, except for the LLOQwhere
Fig. 3 – Sensitivity: (A) LOD (1.5625 μg/ml); (B) LLOQ (3.125 μg/ml).
Table 2 – Regression analysis.
Curcumin Docetaxel
Slope 0.0168 ± 0.00004 0.0222 ± 0.00002
Intercept 0.0002 ± 0.00001 0.0021 ± 0.00009
Correlation coefficient (r2) 0.9997 ± 0.00006 0.9999 ± 0.00004
Each value represents the mean ± SD (n = 6).
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Fig. 4 – Chromatogram of a plasma sample obtained from rat after concomitant administration of a dose of DTX and CCM
via the oral route.
Table 3 – Accuracy.
Nominal
concentration (μg/ml)
Measured
concentration (μg/ml)a
% Recoverya
Curcumin Docetaxel Curcumin Docetaxel
5 5.183 ± 0.024 5.068 ± 0.019 103.66 ± 0.48 101.37 ± 0.38
37.5 37.058 ± 0.225 38.275 ± 0.221 98.822 ± 0.601 102.068 ± 0.589
50 47.610 ± 0.236 48.849 ± 0.252 95.22 ± 0.473 97.699 ± 0.504
a Each value shows the mean ± SD (n = 6).
Table 4 – Precision.
Nominal
concentration (μg/ml)
Day Measured
concentration (μg/ml)a
Precision
valueb
Curcumin Docetaxel Curcumin Docetaxel
Intra-day variance (n = 6)
5 1 5.026 ± 0.039 5.066 ± 0.046 0.78 0.90
2 5.064 ± 0.035 5.081 ± 0.050 0.69 0.98
3 5.022 ± 0.021 5.069 ± 0.044 0.42 0.87
37.5 1 37.078 ± 0.30 37.092 ± 0.339 0.81 0.91
2 37.247 ± 0.320 37.268 ± 0.306 0.86 0.82
3 37.372 ± 0.290 37.275 ± 0.317 0.78 0.85
50 1 50.005 ± 0.303 50.303 ± 0.088 0.60 0.17
2 50.387 ± 0.216 50.241 ± 0.107 0.43 0.21
3 50.177 ± 0.139 50.263 ± 0.145 0.28 0.29
Inter-day variance (n = 6 × 3)
5 – 5.038 ± 0.023 5.072 ± 0.008 0.46 0.16
37.5 – 37.232 ± 0.147 37.212 ± 0.104 0.39 0.28
50 – 50.190 ± 0.191 50.269 ± 0.171 0.38 0.34
a Each value shows the mean ± SD.
b Each value shows the %CV.
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it should not exceed 20% of the CV [34]. All the tested samples
showed the %CV within the accepted limits, suggesting that
the described method was precise.
The effect of minor intentional changes in the described
chromatographic conditions is shown in Table 5. According to
the FDA guideline, “system suitability” and “robustness” are not
necessary for the validation of bioanalytical method [34];
however, these tests were performed to further ensure the re-
liability of our method. Sometimes fluctuation in column
temperature alters the retention time of analytes which may
affect the reliability of analysis. The slight variations in the
column temperature, mobile phase flow rate and mobile phase
composition did not result in considerable differences in the
retention time and peak area ratio of the analytes. Thus, the
described method exhibited robustness.
The stability test of DTX and CCM in the samples placed
in the autosampler was performed at 1, 6, 12, 24 and 48 h
(Table 6).The test was carried out in triplicate at each time point.
The concentration of the sample increased slightly with time
due to a little evaporation of acetonitrile. However, the con-
centration results at various time points were not significantly
different from one another.
4. Conclusion
The present HPLC method for simultaneous evaluation of DTX
and CCM in rat plasma using PTX as an internal standard
proved to be simple, sensitive, precise, accurate, robust and re-
producible in accordance with the FDA guidelines. Furthermore,
the analytes were stable in the samples placed at room tem-
perature over a period of 48 h.Thus, the developed method can
be used for routine analysis of DTX and CCM in rat plasma
samples. Further study on pharmacokinetics after oral admin-
istration of a novel DTX/CCM-loaded oral product to rats will
be performed with this developed method.Fig. 5 – Calibration curve: (A) docetaxel; (B) curcumin.
Table 5 – Robustness testing.
Parameter Setting Curcumin Docetaxel
Retention timea Peak area ratioa Retention timea Peak area ratioa
Column temperature (°C) 38 10.473 ± 0.160 0.842 ± 0.513 14.284 ± 0.203 1.113 ± 0.198
40 10.595 ± 0.322 0.840 ± 0.277 14.294 ± 0.215 1.112 ± 0.265
42 10.603 ± 0.398 0.837 ± 0.421 14.297 ± 0.209 1.112 ± 0.195
Mobile phase flow rate (ml/min) 0.95 10.609 ± 0.261 0.840 ± 0.397 14.285 ± 0.200 1.112 ± 0.196
1.00 10.595 ± 0.322 0.840 ± 0.277 14.294 ± 0.215 1.112 ± 0.265
1.05 10.460 ± 0.225 0.838 ± 0.255 14.300 ± 0.207 1.111 ± 0.236
Mobile phase composition (%, v/v) 39:61 10.451 ± 0.156 0.838 ± 0.222 14.284 ± 0.203 1.113 ± 0.231
40:60 10.595 ± 0.322 0.840 ± 0.277 14.294 ± 0.215 1.112 ± 0.265
41:59 10.609 ± 0.241 0.836 ± 0.267 14.304 ± 0.198 1.112 ± 0.264
a Each value shows the mean ± %CV of each setting (n = 6).
Table 6 – Stability.
Time (h) Concentration (μg/ml) a
Curcumin Docetaxel
1 24.863 ± 0.287 25.063 ± 0.305
6 24.984 ± 0.393 25.180 ± 0.322
12 25.053 ± 0.285 25.554 ± 0.282
24 25.371 ± 0.434 25.902 ± 0.513
48 25.869 ± 0.552 25.955 ± 0.503
a Each value represents the mean ± %CV (n = 3).
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